@childrensnational.bsky.social

@crohnscolitisfdn.bsky.social

#CCCongress2026 #CCCongress26 #CCC2026 #CCC26 #SexDifferences #SexInScience #SoulDog #HeartDog #Bellagio #YearOfTheHorse #Wellness #WellBeing

🧵3/5

...approaches for pediatric #Crohns disease!!

I also enjoyed sharing information about the newly launched
@childrensnational.bsky.social
#GrowthProgram (childrensnational.org/get-care/dep...) !!

#CCCongress2026 #CCCongress26 #SexDifferences #SexInScience #Bellagio #YearOfTheHorse

🧵1/5

I had a wonderful time at the Crohn's and Colitis Congress Revolutionizing #IBD Care Meeting in #LasVegas (1/22/26 - 1/24/26) listening to the latest scientific updates and catching up with my friends & colleagues!!

#CCCongress2026 #CCCongress26 #CCC2026 #CCC26

IV vs SC Vedolizumab for IBD | Docwire News While intravenous and subcutaneous vedolizumab had largely similar safety and efficacy for IBD, there were a few key differences in outcomes.

Real-world data presented at #CCCongress26 suggest IV and SC #vedolizumab have similar overall safety and efficacy in IBD, but IV use was linked to higher hospitalization and steroid use (#UlcerativeColitis) and higher shock rates (#CrohnsDisease). #IBDSky #GISky

DBH Inhibitor for Ulcerative Colitis | Docwire News In results from a phase 1b trial, dopamine beta-hydroxylase inhibitor, APL-1401, demonstrated early efficacy signals for patients with moderate-to-severe active ulcerative colitis.

Phase 1b data suggest early efficacy signals for APL-1401, a first-in-class DBH inhibitor, in moderate-to-severe #UlcerativeColitis. Results presented at the #CCCongress26 support further dose evaluation. #GISky #IBDSky

CATHARSIS Meets Measures for Continuation | Docwire News With successful randomization, masking, and retention, the CATHARSIS trial has proved it warrants continuation.

Early CATHARSIS trial data presented at #CCCongress26 suggest combining biologics with structured #BrainGut behavioral therapy may improve well-being in moderate-severe #CrohnsDisease. High feasibility, satisfaction, and retention reported. #IBDSky #GISky

Novel G9a-Inhibitor Shows Promise | Docwire News According to data presented at the 2026 Crohn’s and Colitis Congress, ATH-063 showed preliminary potential with a favorable pharmacokinetics profile.

Phase 1 data presented at #CCCongress26 highlight ATH-063, a first-in-class oral G9a inhibitor. In healthy volunteers, it showed favorable PK, no safety signals, and strong FoxP3+ Treg activation—supporting further study in biologics-resistant IBD.

#IBDSky #GISky

GLP-1 RAs and Crohn’s Disease | Docwire News As reported at the 2026 Crohn’s and Colitis Congress, GLP-1 RAs are potentially beneficial as an adjunct to Crohn’s disease management for patients with overweight or obesity.

Real-world data presented at #CCCongress26 suggest #GLP1 RAs may benefit #CrohnsDisease patients with overweight/obesity. #GLP1RA use was linked to lower steroid dependence, fewer hospitalizations, and improved durability of advanced IBD therapy. #IBDSky #GISky

Reflecting on my time at #CCCongress26 in Las Vegas💙As a #patient #advocate & someone living w/ #IBD it’s a privilege I don’t take lightly🥹To witness cutting-edge research🔬emerging treatments🧬 & the commitment of clinicians & researchers who care about patients is powerful💥

GLP-1RAs for IBD | Docwire News Use of GLP1 receptor agonists was associated with improved inflammatory bowel disease-related outcomes.

Real-world data presented at #CCCongress26 suggest GLP-1 receptor agonists may improve #InflammatoryBowelDisease outcomes. In IBD, #GLP1 RA use was linked to lower steroid use, hospitalizations, surgery, and mortality, supporting further study. #GISky #IBDSky

Focus Groups Expose Care Gaps for LGBTQ+ People Living With IBD Patients report delayed diagnosis, ineffective treatment, and discrimination

People who identify as #LGBTQ+ face distinct and compounding challenges when living with IBD, according to a qualitative study. @crohnscolitisfdn.bsky.social @victorchedidmd.bsky.social #CCCongress26
www.medpagetoday.com/meetingcover...

GLP-1 Therapy May Offer Added Benefit in IBD Beyond Weight Loss Real-world analyses suggest link to reduced steroid use, fewer hospital stays, lower mortality

GLP-1-based therapies may offer benefits in IBD that extend beyond their metabolic indication, according to two poster presentations at #CCCongress26.
www.medpagetoday.com/meetingcover...

Missed #CCCongress26? We've got you covered.

Catch up on our reporting ⬇️
@crohnscolitisfdn.bsky.social

Live from #CCCongress26! Patient Reporter Ian Goldstein talks with Board of Trustees Chair Amber Backhaus about leadership, progress, and hope for everyone affected by IBD.

Prior Biologic Use Tied to JAK Inhibitor Benefit in Ulcerative Colitis In certain patients, JAK inhibitor rescue medications seem to be more effective, researcher says

Prior exposure to anti-TNF therapy was associated with a lower risk of colectomy among patients receiving JAK inhibitor rescue therapy for acute severe ulcerative colitis, according to findings. #CCCongress26
https://www.medpagetoday.com/meetingcoverage/ccc/119560

Our IBD attendings presenting and having fun at #CCCongress2026 #CCCongress26. Thanks @crohnscolitisfdn.bsky.social !!!

It’s Day 2 of #CCCongress26! From cutting-edge research to powerful patient stories, the Crohn’s & Colitis Congress is driving progress in IBD treatment and understanding.

As a #fistula patient myself, I know all too well the trauma that #IBD patients go through when living w/ #perianal disease. So valuable for the patient perspective & mental health recommendations to be shared & discussed at #CCCongress26

@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social

So insightful to hear Dr. Marla Dubinsky summarize the the right drug at the right time in #IBD So many considerations for patients & clinicians #CCCongress26

@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social

Grateful for Dr. Larry Kim’s leadership of the @amergastroassn.bsky.social 🎉 Beyond appreciative of the @crohnscolitisfdn.bsky.social incredible commitment to #IBD patients. Thank you Dr. Alan Moss (Chief Scientific Officer) for leading IBD scientific advancements at the Foundation🥹 #CCCongress26

Key summaries of all of the latest advancements in treatment for both #CD and #UC at #CCCongress26 at #IBD 101, including bone marrow transplant success for CD (in Europe)🎉

@amergastroassn.bsky.social
@crohnscolitisfdn.bsky.social

📣 It’s #CrohnsColitisAwarenessWeek! Ready to take your IBD knowledge to the next level?
Join us at the 2026 Crohn’s & Colitis Congress
✨ Register by Dec. 9 & save up to $166
✨ Hotel deadline: Dec. 18
👉 crohnscolitiscongress.org?utm_medium=B...

#IBD #CCCongress26 #CrohnsColitisAwarenessWeek

Very excited about the 2026 Crohn’s & Colitis Congress® in Las Vegas, Jan. 22–24! Only a few days left of the Advanced discount period, closing Tuesday, October 21. #CCCongress26 is THE MEETING to learn and lead the future of IBD. Register ASAP 🔗bit.ly/4m85s1N!

Home 2026 Join colleagues across the entire spectrum of clinical care and science at the premier conference on inflammatory bowel disease (IBD).

Join me & keynote speaker Dr. Florian Rieder at #CCCongress26, Jan. 22-24 in Vegas. @ibd-flomd.bsky.social does an outstanding job bridging #IBD basic science and clinical research, so this is sure to be a great talk Register by 10/21 & SAVE: 🔗 bit.ly/4m85s1N
#IBDsky #GIsky #Gastrosky

a sign that says welcome to fabulous las vegas ALT: a sign that says welcome to fabulous las vegas

Lastly, it has been wonderful chairing the Congress with my fellow co-chairs, Tina Ha & Jessica Allegretti. The planning for #CCCongress26 in #Vegas has already begun!